Investigational drug · Phase 3
Rezvilutamide
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC).
Phase 3Last checked: Nov 19, 2026Latest source record: May 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
21
Any phase or sponsor naming "Rezvilutamide"
First trial start
2025
Dec 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rezvilutamide", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rezvilutamide" as an intervention, largest first.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT05406999 · 900 participants (planned) · Start Feb 1, 2020 · Primary completion Dec 31, 2026
Drug: ADT; Abiraterone Acetate and 6 more · For: Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer and 1 more
Sites: Nanjing, China
- Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07490210 · 300 participants (planned) · Start May 1, 2026 · Primary completion May 31, 2032
Drug: Rezvilutamide + ADT · For: Oligometastatic Prostate Cancer
Sites: Shanghai, China
- A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate CancerPivotal-lookingRecruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07241416 · 206 participants (planned) · Start Dec 5, 2025 · Primary completion Mar 2027
Drug: Rezvilutamide Tablets; Enzalutamide Soft Capsules · For: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Sites: Beijing, China
- Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC PatientsPivotal-lookingRecruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06350825 · 200 participants (planned) · Start Jan 1, 2016 · Primary completion Dec 31, 2027
Drug: ADT+second-generation antiandrogens ± chemotherapy · For: Metastatic Prostate Cancer; Therapy, Directly Observed
Sites: Nanjing, China
- Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPCPivotal-lookingRecruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT05983783 · 200 participants (planned) · Start Aug 1, 2023 · Primary completion Dec 31, 2025
Drug: Docetaxel; Rezvilutamide · For: Metastatic Prostate Cancer; Hormone Sensitive Prostate Cancer; Chemotherapy Effect
Sites: Nanjing, China
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP PatientsPivotal-lookingRecruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT06832774 · 192 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2027
Drug: Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). · For: Prostate Cancer Metastatic Disease
Sites: Shanghai, China
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07428642 · 168 participants · Start Sep 1, 2020 · Primary completion Dec 3, 2025
Drug: Androgen Deprivation Therapy; Apalutamide and 4 more · For: Metastatic Hormone-Sensitive Prostate Cancer; Prostate Cancer
Sites: Wenzhou, China
Jianbin BiAcademic, hospital or other
NCT06134271 · 160 participants (planned) · Start Nov 15, 2023 · Primary completion Apr 30, 2025
Drug: Rezvilutamide; Rezvilutamide plus abiraterone and 1 more · For: Metastatic Hormone-Sensitive Prostate Cancer
- Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPCPivotal-lookingRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT06992232 · 144 participants (planned) · Start Aug 1, 2024 · Primary completion Jul 31, 2027
Drug: Intense androgen deprivation therapy · For: Prostate Cancer Metastatic Disease
Sites: Nanjing, China
- CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07268794 · 112 participants (planned) · Start Nov 30, 2025 · Primary completion Apr 30, 2027
Drug: Androgen Deprivation Therapy (ADT); Docetaxel and 1 more · For: Metastatic Prostate Cancer; Prostate Cancer (Adenocarcinoma); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.
Yang X, He Z, Chen J, et al. · BJU Int 2026
- Deep and ultra-deep PSA responses as prognostic biomarkers in metastatic hormone-sensitive prostate cancer. A systematic review and implications for treatment personalization.
Esteban-Villarrubia J, Wu Jin F, Lorente D, et al. · Cancer Treat Rev 2026
- Rezvilutamide in metastatic hormone-sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines.
Mi L, Li S, Huo B · BJU Int 2026
- Rezvilutamide combined with ADT in an HIV-positive patient with high-volume mHSPC on efavirenz-based antiretroviral therapy: a case report.
Zhang H, He T, Li Z, et al. · Front Oncol 2026
- Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer: a retrospective multicenter cohort study.
Wang B, Xia D, Pan Y, et al. · Transl Androl Urol 2026
- Impact of hepatotoxicity and lipid metabolism-related toxicity on survival and quality of life in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial: a post hoc analysis.
Wu JL, Jiang SS, Luo H, et al. · BMC Med 2026
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.